ProCE Banner Activity

Our Thoughts on Cytokine Release Syndrome With BCMA-Targeted Therapies for Relapsed/Refractory Multiple Myeloma

Clinical Thought

Review this expert commentary from clinical pharmacists on cytokine release syndrome and monitoring patients receiving BCMA-targeted therapies for relapsed/refractory multiple myeloma.

Released: June 19, 2023



Donald C. Moore

Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP

Clinical Oncology Pharmacy Manager
Atrium Health Levine Cancer Institute
Charlotte, North Carolina

Victoria Nachar

Victoria Nachar, PharmD, BCOP

Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Provided by

Provided by ProCE

ProCE Banner


Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb


Clinical Care Options, LLC

ProCE Banner

Hematology/Oncology Pharmacy Association (HOPA)

ProCE Banner